Iovance Biotherapeutics Inc (IOVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.59B
Last updated: Nov 17, 2026 at 11:06 AM ET
Iovance Biotherapeutics Inc (IOVA) Stock Forecast
Analysts expect Iovance Biotherapeutics (IOVA) to earn -$0.38 per share in the fiscal year ending Dec 31, 2026, on revenue of $418.60M. Of 9 analysts, 7 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 78% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 5 | 55.6% |
| Hold | 2 | 22.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 41.9%.
- Fiscal year ending Dec 31, 2026
- -$0.38
- EPS consensus, revenue $418.60M
- Fiscal year ending Dec 31, 2027
- -$0.11
- EPS consensus, revenue $593.84M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.38 | -$0.40 to -$0.37 | 8 | $418.60M | $414.86M to $422.72M | 8 |
| Dec 31, 2027 | -$0.11 | -$0.22 to -$0.04 | 8 | $593.84M | $564.40M to $622.19M | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.08 for the quarter ending Dec 31, 2026 to -$0.04 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.08 | -$0.12 to -$0.04 | 12 | $131.23M | $122.29M to $141.61M | 11 |
| Mar 31, 2027 | -$0.04 | -$0.08 to -$0.02 | 7 | $133.90M | $124.93M to $145.21M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 6 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.48.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.38 | -$0.45 | -$0.46 | -$0.50 | -$0.48 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.11 | -$0.20 | -$0.24 | -$0.29 | -$0.27 | N/A |
| Quarter ending Mar 31, 2027 | -$0.04 | -$0.08 | -$0.08 | -$0.09 | -$0.09 | N/A |
Frequently Asked Questions About IOVA
What is the IOVA stock forecast?
Consensus analyst estimates put Iovance Biotherapeutics's EPS at -$0.38 for the fiscal year ending Dec 31, 2026, on revenue of $418.60M. The consensus rating from 9 analysts is Buy.
How do analysts rate IOVA stock?
Of 9 analysts covering Iovance Biotherapeutics, 2 rate it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IOVA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.38, with estimates from -$0.40 to -$0.37 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.11, with estimates from -$0.22 to -$0.04 from 8 analysts.
What revenue do analysts expect from Iovance Biotherapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $418.60M, with estimates from $414.86M to $422.72M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $593.84M, with estimates from $564.40M to $622.19M.
How many analysts cover IOVA?
9 analysts rate Iovance Biotherapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IOVA pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts